# Anti-GPRC5D CAR-T Cells (CT071) in Participants With RRMM or RRpPCL

> **NCT06333509** · PHASE1,PHASE2 · NOT_YET_RECRUITING · sponsor: **CARsgen Therapeutics Co., Ltd.** · enrollment: 166 (estimated)

## Conditions studied

- Multiple Myeloma
- Primary Plasma Cell Leukemia

## Interventions

- **BIOLOGICAL:** CT071

## Key facts

- **NCT ID:** NCT06333509
- **Lead sponsor:** CARsgen Therapeutics Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2024-04-15
- **Primary completion:** 2027-06-15
- **Final completion:** 2027-12-31
- **Target enrollment:** 166 (ESTIMATED)
- **Last updated:** 2024-03-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06333509

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06333509, "Anti-GPRC5D CAR-T Cells (CT071) in Participants With RRMM or RRpPCL". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06333509. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*